Search Results - "HALFON, P."

HPV self‐sampling or the Pap‐smear: A randomized study among cervical screening nonattenders from lower socioeconomic groups in France by Sancho‐Garnier, H., Tamalet, C., Halfon, P., Leandri, F.X., Retraite, L. Le, Djoufelkit, K., Heid, P., Davies, P., Piana, L.

“…Today in France, low attendance to cervical screening by Papanicolaou cytology (Pap‐smear) is a major contributor to the 3,000 new cervical cancer cases and…”
Get full text

Impact of common risk factors of fibrosis progression in chronic hepatitis C by Rüeger, S, Bochud, P-Y, Dufour, J-F, Müllhaupt, B, Semela, D, Heim, M H, Moradpour, D, Cerny, A, Malinverni, R, Booth, D R, Suppiah, V, George, J, Argiro, L, Halfon, P, Bourlière, M, Talal, A H, Jacobson, I M, Patin, E, Nalpas, B, Poynard, T, Pol, S, Abel, L, Kutalik, Z, Negro, F

“…The natural course of chronic hepatitis C varies widely. To improve the profiling of patients at risk of developing advanced liver disease, we assessed the…”
Get more information

Magnetically localized and wash-free fluorescence immunoassay (MLFIA): proof of concept and clinical applications by Delshadi, S, Fratzl, M, Ramel, O, Bigotte, P, Kauffmann, P, Kirk, D, Masse, V, Brenier-Pinchart, M P, Fricker-Hidalgo, H, Pelloux, H, Bruckert, F, Charrat, C, Cugat, O, Dempsey, N M, Devillers, T, Halfon, P, Leroy, A, Weidenhaupt, M, Marche, P N

“…Immunoassays are used for many applications in various markets, from clinical diagnostics to the food industry, generally relying on gold-standard ELISAs that…”
Get more information

The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non‐invasive fibrosis biomarkers: an international study of 2411 cases by Sebastiani, G., Castera, L., Halfon, P., Pol, S., Mangia, A., Di Marco, V., Pirisi, M., Voiculescu, M., Bourliere, M., Alberti, A.

“…Aliment Pharmacol Ther 2011; 34: 1202–1216 Summary Background  Performance of non‐invasive fibrosis biomarkers may be influenced by aetiology of chronic liver…”
Get full text

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes by SIMMONDS, Peter, BUKH, Jens, MIZOKAMI, Masashi, MURPHY, Donald G, OKAMOTO, Hiroaki, PAWLOTSKY, Jean-Michel, PENIN, Francois, SABLON, Erwin, SHIN-I, Tadasu, STUYVER, Lieven J, THIEL, Heinz-Jürgen, VIAZOV, Sergei, COMBET, Christophe, WEINER, Amy J, WIDELL, Anders, DELEAGE, Gilbert, ENOMOTO, Nobuyuki, FEINSTONE, Stephen, HALFON, Phillippe, INCHAUSPE, Geneviève, KUIKEN, Carla, MAERTENS, Geert

“…International standardization and coordination of the nomenclature of variants of hepatitis C virus (HCV) is increasingly needed as more is discovered about…”
Get full text

Magnetically localized and wash-free fluorescent immuno-assay: From a research platform (MLFIA) to a multiplexed POC system (MagIA) by Fratzl, M., Bigotte, P., Gorbenkov, R., Goubet, G., Halfon, P., Kauffmann, P., Kirk, D., Masse, V., Payet-Burin, X., Ramel, O., Delshadi, S.

“…Sexually transmitted infections (STI) remain one of the world's public health priorities: Nearly 400 million people are infected not only in emerging, but also…”
Get full text

Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages by Poynard, Thierry, Halfon, Philippe, Castera, Laurent, Munteanu, Mona, Imbert-Bismut, Francoise, Ratziu, Vlad, Benhamou, Yves, Bourliere, Marc, de Ledinghen, Victor, FibroPaca Group

“…The area under the ROC curve (AUC) is widely used as an estimate of the diagnostic value for fibrosis markers. Whether there is variability in the AUC related…”
Get full text

Hepatitis B vaccination status and vaccine immune response among children in rural Senegal by Perieres, L, Coste, M, Ndiour, S, Halfon, P, Sokhna, C, Ba, E, Diallo, A, Boyer, S

“…Abstract Background Hepatitis B vaccination during childhood is key to reduce the prevalence of Hepatitis B virus (HBV) infection. In Senegal, a highly endemic…”
Get full text

Monkeypox virus infection by Cacoub, P, Halfon, P

Get full text

Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir by Maasoumy, B., Cobb, B., Bremer, B., Luk, K., Halfon, P., Aslam, S., Manns, M. P., Cornberg, M., Wedemeyer, H.

“…Summary Background Early on‐treatment virological response is one of the most important predictors for sustained virological response (SVR) to treatment of…”
Get full text

Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge by Kostine, M., Chiche, L., Lazaro, E., Halfon, P., Charpin, C., Arniaud, D., Retornaz, F., Blanco, P., Jourde-Chiche, N., Richez, C., Stavris, C.

“…With “checkpoint inhibitors” targeting PD1/PD-1-ligands or CTLA-4/CD28 pathways, immunotherapy has profoundly modified therapeutic strategies in oncology…”
Get full text

Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C by Sebastiani, G., Halfon, P., Castera, L., Mangia, A., Di Marco, V., Pirisi, M., Voiculescu, M., Bourliere, M., Alberti, A.

“…Aliment Pharmacol Ther 2012; 35: 92–104 Summary Background  Preliminary data suggest that performance of non‐invasive markers for liver fibrosis in hepatitis C…”
Get full text

Drug-resistance genotyping in HIV-1 therapy : the VIRADAPT randomised controlled trial by DURANT, J, CLEVENBERGH, P, HALFON, P, DELGIUDICE, P, PORSIN, S, SIMONET, P, MONTAGNE, N, BOUCHER, C. A. B, SCHAPIRO, J. M, DELLAMONICA, P

“…Growing evidence has linked HIV-1 resistance mutations and drug failure. The use of genotypic-resistance analysis to assist therapeutic decision-making in…”
Get full text

Risk of falls for hospitalized patients: A predictive model based on routinely available data by Halfon, Patricia, Eggli, Yves, Van Melle, Guy, Vagnair, André

“…The incidence rate of falls is often used as an indicator of nursing care outcome. Comparing outcome between different settings should, however, make allowance…”
Get full text

Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C by Shlomai, A., Halfon, P., Goldiner, I., Zelber-Sagi, S., Halpern, Z., Oren, R., Bruck, R.

“…Serum bile acids (SBAs) are commonly elevated in cholestatic liver diseases, but it is unclear if SBA levels are also elevated in noncholestatic chronic liver…”
Get full text

Hepatitis C virus infection, 1989-2019: From discovery to eradication by Cacoub, P, Halfon, P

Get full text

424 OPTIMIZED HBsAg TITER MONITORING IMPROVES INTERFERON THERAPY IN PATIENTS WITH CHRONIC HEPATITIS DELTA by Ouzan, D, Pénaranda, G, Joly, H, Khiri, H, Halfon, P

Get full text

Retreatment with Direct Active Antivirals of genotype 1, 3 and 4 chronic hepatitis C patients who previously failed an anti-NS5A-containing regimen in real world by Halfon, P, Scholtes, C, Izopet, J, Larrat, S, Penaranda, G, Trimoulet, P, Zoulim, F, Alric, L, Metivier, S, Bourliere, M, Leroy, V, Ouzan, D, de Ledinghen, V, Mohamed, S, Thelu, M.-A, Abravanel, F

Get full text

Retreatment of hepatitis C virus daa failures in real life: easy and difficult to cure patients by Ouzan, D, Penaranda, G, Lefolgoc, G, Antoni, M, Delasalle, P, Fontanges, T, Cerdan, P, Toulemonde, P, Bresson-Hadni, S, Beorchia, S, Boyer, N, Hanslik, B, Joly, H, Liautard, J, Baesjou, S, Bonny, C, Halfon, P, Renou, C, Bourliere, M

Get full text

Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation by POYNARD, T., HALFON, P., CASTERA, L., CHARLOTTE, F., BAIL, B. LE, MUNTEANU, M., MESSOUS, D., RATZIU, V., BENHAMOU, Y., BOURLIÈRE, M., LEDINGHEN, V. DE

“…Summary Background The area under the receiver operating characteristic (ROC) curve is widely used as an estimate of the diagnostic value for fibrosis markers…”
Get full text